Obstructive Sleep Apnea

• Airway Collapse Mechanism: During wakefulness, the pharyngeal airway is maintained patent through active contraction of dilator muscles (genioglossus, soft palate muscles, lateral pharyngeal wall muscles) innervated by the hypoglossal nerve, counteracting the collapsing force of negative intraluminal pressure generated during inspiration. During sleep, particularly non-rapid eye movement (NREM) sleep stages 2-3, there is physiologic atonia of skeletal muscles and reduced activation of pharyngeal dilator muscles, creating a mechanical disadvantage. In predisposed individuals, the critical closing pressure (Pcrit) of the pharynx—the extraluminal pressure at which the airway collapses—is abnormally high (less negative), meaning modest negative intrapharyngeal pressures during inspiration exceed the structural stability of the airway. This results in dynamic airway obstruction with continued respiratory effort against the closed airway (obstructive apnea) rather than cessation of breathing effort. The anatomic factors contributing to increased Pcrit include: (1) decreased cross-sectional airway area from obesity (increased soft tissue volume in the neck and tongue hypertrophy), retrognathia, micrognathia, or tonsillar enlargement; (2) altered airway compliance from soft tissue laxity or edema; and (3) abnormal pharyngeal wall geometry from posteriorly positioned soft palate or lateral pharyngeal wall collapse.

• Chemoreceptor Hypersensitivity and Respiratory Instability: During each apneic episode, progressive hypoxemia and hypercapnia develop, eventually triggering central respiratory drive through chemoreceptor activation (peripheral carotid/aortic bodies and central medullary chemoreceptors responding to PaO₂ <60 mmHg and PaCO₂ elevation). This powerful respiratory stimulus overcomes the depressant effect of sleep and causes brief arousal (5-15 second awakening), which restores pharyngeal muscle tone and airway patency. However, upon return to sleep, the Pcrit again exceeds the collapsing pressure, and the cycle repeats. This repetitive cycle (apnea → hypoxemia/hypercapnia → arousal → airway opening → sleep resumption → apnea) constitutes the characteristic pattern of OSA. Importantly, the loop gain (responsiveness of ventilation to changes in blood gases and pH) is often abnormally high in OSA patients, meaning even small deviations in PaCO₂ or PaO₂ provoke disproportionate ventilatory responses, promoting ventilatory instability and perpetuating apneas. This is distinct from central sleep apnea, where there is reduced respiratory drive without airway obstruction.

• Hypoxemia, Hypercapnia, and Intrathoracic Pressure Swings: Each apneic event results in transient but cumulative hypoxemia (oxygen desaturation), which may be severe (nadir SpO₂ as low as 50-60% in moderate-severe OSA) and is followed by rapid reoxygenation upon airway reopening. The degree of oxygen desaturation correlates with arousability and cardiovascular stress. Concurrently, the obstructed respiratory effort continues despite airway closure, generating extreme negative intrathoracic pressures (up to -60 cm H₂O) that persist until arousal. These markedly negative intrathoracic pressures increase left ventricular transmural pressure, increasing left ventricular afterload and myocardial oxygen demand acutely; they also increase venous return to the right heart, potentially causing right ventricular dilation. The hypoxemia-reoxygenation cycling creates intermittent hypoxia, a potent trigger for oxidative stress, sympathetic nervous system activation, and systemic inflammation that extends pathologic effects beyond the sleep period into waking hours.

• Sympathetic Nervous System Hyperactivation and Vascular Consequences: The repeated arousals, hypoxemia, and hypercapnia in OSA trigger marked sympathetic nervous system activation, manifest as increased muscle sympathetic nerve activity (MSNA) that persists into waking hours even in untreated patients. Catecholamine surges during each apneic event and arousal cause acute hypertension (blood pressure may increase 20-50 mmHg), tachycardia, and arrhythmia risk. Chronic intermittent hypoxia activates hypoxia-inducible factor (HIF-1α) and increases production of vascular endothelial growth factor (VEGF) and reactive oxygen species (ROS), promoting systemic vascular inflammation, endothelial dysfunction, and atherosclerosis acceleration. The chronic sympathetic overdrive and oxidative stress contribute to sustained daytime hypertension (present in 50-90% of OSA patients), which is often refractory to antihypertensive medications and improves with CPAP therapy. Additionally, hypoxia-induced inflammation upregulates tissue factor and thrombin-antithrombin complexes, promoting a prothrombotic state and increasing venous thromboembolism and acute thrombotic cardiovascular event risk.

• Metabolic and Endocrine Derangements: The sleep fragmentation, intermittent hypoxia, and sympathetic activation of OSA disrupt normal endocrine and metabolic homeostasis. Insulin sensitivity decreases via multiple mechanisms—hypoxia-induced ROS production, sympathetic-mediated suppression of parasympathetic pancreatic beta-cell function, and sleep fragmentation-induced alterations in hypothalamic-pituitary signaling—resulting in insulin resistance and increased type 2 diabetes mellitus risk independent of obesity. Similarly, leptin resistance develops despite elevated circulating leptin levels, impairing satiety signaling and contributing to weight gain. Growth hormone secretion is reduced (normally concentrated in NREM sleep), whereas cortisol levels are elevated due to chronic stress-axis activation, perpetuating insulin resistance and visceral adiposity. Ghrelin (appetite-stimulating hormone) increases. These derangements create a vicious cycle where weight gain exacerbates OSA severity, which worsens metabolic dysfunction and further promotes weight gain.

• Arrhythmia Mechanisms: OSA creates a perfect electrical storm for arrhythmia generation: the negative intrathoracic pressure swings increase venous return and chamber dilation (mechanical stretch activates arrhythmogenic pathways); hypoxemia and sympathetic surges increase automaticity; the repetitive arousal-associated heart rate fluctuations create electrical instability; and atrial stretch from right heart dilation in severe OSA predisposes to atrial fibrillation. Atrial fibrillation is present in 20-50% of moderate-severe OSA patients and often recurs despite cardioversion or antiarrhythmic therapy until OSA is treated. The arrhythmia-promoting effects of OSA are maximal during sleep and explain the epidemiologic link between untreated OSA and sudden nocturnal cardiac death.

• Pulmonary Hypertension in Severe OSA: In a subset of patients with severe OSA (particularly those with additional risk factors like obesity hypoventilation syndrome or concurrent COPD), the cumulative effects of repetitive hypoxemia, hypercapnia, sympathetic activation, and endothelial dysfunction lead to remodeling of the pulmonary vasculature, with medial hypertrophy and intimal proliferation. This results in elevated pulmonary vascular resistance and eventually pulmonary hypertension, which can progress to right heart failure if untreated. Pulmonary hypertension in OSA is typically mild (mean PAP 20-35 mmHg) but can be severe in advanced cases.

• Obesity: The single most important modifiable risk factor, present in 60-90% of OSA patients. Obesity increases neck circumference and increases soft tissue volume in the pharynx, tongue, and soft palate, reducing airway cross-sectional area and increasing Pcrit. The relationship between body mass index (BMI) and OSA severity is nonlinear but strong; each 1 kg/m² increase in BMI increases OSA risk by ~4%. Conversely, weight loss of 10-15% can reduce apnea-hypopnea index (AHI) by 30-50%, making weight management a cornerstone of therapy. Abdominal obesity (increased visceral fat) is particularly associated with OSA severity, independent of overall BMI.

• Anatomic and Craniofacial Abnormalities: Structural features that reduce pharyngeal cross-sectional area substantially increase OSA risk. Micrognathia (small mandible) or retrognathia (posterior positioning of mandible) narrow the oropharynx; these may be isolated or part of genetic syndromes (Pierre Robin sequence, Treacher Collins syndrome). Macroglossia (enlarged tongue) from Down syndrome, amyloidosis, or hypothyroidism reduces airway space. Tonsillar enlargement (grades 3-4) or adenoid hypertrophy (particularly in children, but also in adults with sleep apnea) obstructs the nasopharynx and oropharynx. Nasal obstruction from septal deviation, rhinitis, or polyps increases resistance to nasal breathing and promotes oral breathing (which further compromises airway mechanics). Increased soft palate length or lateral pharyngeal wall collapse are anatomic features identifiable on imaging that increase collapse susceptibility. These anatomic factors often have a genetic component and explain why some individuals develop OSA at lower BMI levels (<30 kg/m²), a phenotype termed nonobese OSA (10-20% of OSA population).

• Male Gender: Men are 2-3 times more likely to have OSA than women, a disparity attributed to: (1) anatomic factors—men have longer airways and greater neck circumference at the same BMI; (2) hormonal factors—estrogen has protective effects on upper airway muscle tone and chemoresponsiveness, explaining the increased OSA incidence in postmenopausal women not on hormone replacement therapy; (3) positional factors—men are more likely to be supine sleepers, increasing OSA risk. The gender disparity narrows after menopause, suggesting estrogen's protective role.

• Age: OSA prevalence increases substantially with advancing age, rising from ~5% in young adults to 20-30% in individuals older than 65 years. Aging is associated with loss of muscle mass (including pharyngeal dilator muscles), increased soft tissue laxity, and changes in sleep architecture and respiratory control. However, the elderly often present with milder symptoms despite more apneas, attributed to reduced arousability with age.

• Supine Sleep Position: Supine sleep predisposes to pharyngeal collapse because gravity-dependent tissue retrodisplacement is maximal in supine position, whereas lateral decubitus or prone positions reduce OSA severity by 50-75% in position-dependent (postural) OSA. Approximately 50% of patients have positional OSA (defined as AHI supine ≥2 times lateral AHI). This is therapeutically exploitable through positional devices.

• Alcohol and Sedative Use: Alcohol suppresses pharyngeal dilator muscle activity and reduces arousability, worsening both AHI and oxygen desaturation severity, particularly in the early night when alcohol concentration peaks. Benzodiazepines and opioids have similar effects and are relatively contraindicated in OSA patients. Even patients without baseline OSA may develop apneas after alcohol or sedative ingestion, creating perioperative risk.

• Medical Comorbidities:
• Hypothyroidism: Causes macroglossia, myxedematous soft tissue edema, and reduced central respiratory drive; TSH >10 mIU/L warrants thyroid hormone replacement before attributing OSA to other factors.
• Acromegaly: Growth hormone excess causes tongue enlargement and soft tissue hypertrophy; OSA is present in 50-60% of acromegaly patients.
• Polycystic ovary syndrome (PCOS): Associated with insulin resistance and visceral obesity; OSA prevalence is elevated even after controlling for BMI.
• Down syndrome and other genetic conditions: Increased prevalence due to craniofacial abnormalities, hypotonia, and obesity.
• Chronic kidney disease and end-stage renal disease: Fluid retention causes neck edema and upper airway obstruction; additional risk from anemia (reduced oxygen carrying capacity).
• Congestive heart failure: Cheyne-Stokes respiration and central sleep apnea are common, but OSA also occurs; the relationship is bidirectional.

• Smoking: Active smoking increases OSA risk via upper airway inflammation and edema, though the mechanism is less robust than obesity. Smoking cessation improves OSA severity modestly.

• Nasal Obstruction: Deviated septum, turbinate hypertrophy, allergic rhinitis, and chronic rhinosinusitis increase upper airway resistance and OSA susceptibility.

• Snoring: The most common and often the presenting symptom, reported by >80% of OSA patients, though not all snorers have OSA (estimated 5-10% of snorers have clinically significant OSA). Snoring results from vibration of pharyngeal tissues as air moves through the partially narrowed airway during inspiration. It is typically loud (audible from another room), persistent (every night), and disruptive to bed partners. Importantly, snoring severity does not correlate with OSA severity; some patients with severe OSA have quiet apneas. The absence of snoring does not exclude OSA, though it is present in the vast majority of cases.

• Witnessed Apneas: Bed partners frequently report episodes of silence (apnea lasting 10-30+ seconds) followed by loud gasping or choking as the patient arouses and airway reopens. This pattern—silence punctuated by sudden, often violent gasping—is classic for OSA and highly specific. Patients may also be witnessed to have witnessed arousals with body movements or restless sleep with frequent position changes. These witnessed events are highly sensitive for severe OSA and often prompt urgent medical evaluation.

• Excessive Daytime Somnolence (EDS): Characterized by irresistible urge to sleep during the day, difficulty maintaining wakefulness, and unintended sleep episodes during activities. EDS results from chronic sleep fragmentation (arousals prevent deep restorative sleep) and sleep deprivation. However, EDS is paradoxically absent in 25-40% of patients with moderate-severe OSA (particularly men and older adults), likely due to attenuated arousability—these individuals have more apneas but fewer arousals and thus less sleep fragmentation, though they still incur cardiovascular consequences of hypoxemia and sympathetic activation. This dissociation between AHI severity and symptom severity is an important board concept; absence of EDS does not exclude hemodynamically significant OSA requiring treatment.

• Unrefreshing Sleep and Non-Restorative Sleep: Patients report waking in the morning

Step 1 — risk stratification, not diagnosis

• Screening instruments: the STOP-BANG questionnaire (Snoring, Tiredness, Observed apnea, Pressure, BMI, Age, Neck circumference, Gender) and the Epworth Sleepiness Scale quantify pretest probability and subjective sleepiness. Neither establishes the diagnosis — a question stem offering "Epworth score" as the diagnostic answer is a distractor.

Step 2 — objective testing

• In-laboratory attended polysomnography (PSG): the gold standard. Records EEG/EOG/EMG (sleep staging and arousals), nasal pressure and thermistor airflow, thoracoabdominal effort belts, oximetry, and ECG. The defining finding is absent airflow with persistent respiratory effort — the mechanical signature that separates obstructive from central events.
• Home sleep apnea testing (HSAT): the American Academy of Sleep Medicine (AASM) 2017 diagnostic guideline endorses HSAT in uncomplicated adults with high pretest probability of moderate–severe OSA. PSG is required when cardiopulmonary disease, hypoventilation, neuromuscular disease, opioid use, or another sleep disorder is suspected, and after a negative or technically inadequate HSAT (HSAT underestimates severity because total sleep time is not measured).

Scoring and thresholds

• Apnea–hypopnea index (AHI): events per hour of sleep. Diagnosis requires AHI ≥5 with symptoms or associated comorbidity (hypertension, mood or cognitive disturbance, coronary disease, stroke, atrial fibrillation, diabetes), or AHI ≥15 regardless of symptoms.
• Severity grading: mild AHI ≥5 to <15, moderate ≥15 to <30, severe ≥30.
• Respiratory disturbance index (RDI) additionally counts respiratory effort–related arousals (RERAs), so RDI ≥ AHI; RERA-predominant disease is upper airway resistance syndrome.
• Hypopnea definition: AASM permits ≥30% airflow reduction with ≥3% desaturation or an arousal; the more restrictive ≥4% desaturation rule is also accepted and is the traditional payer criterion — the same study can therefore yield two different AHIs.
• Pediatrics: AHI >1/hour is abnormal; adult cut-offs do not apply.

Adjunctive workup

• Targeted labs: TSH for hypothyroidism, hemoglobin/hematocrit for secondary erythrocytosis, and serum bicarbonate or ABG when awake hypercapnia (obesity hypoventilation syndrome, PaCO₂ >45 mmHg) is suspected. Echocardiography if pulmonary hypertension or right heart failure is suggested clinically.

Behavioral foundation (applies to every patient)

• Weight loss: the only intervention that modifies the underlying anatomic substrate by lowering Pcrit; lifestyle programs, and increasingly incretin-based pharmacotherapy (GLP-1/GIP receptor agonists such as tirzepatide, which carries an FDA indication for moderate–severe OSA with obesity), reduce AHI substantially but rarely cure severe disease.
• Positional therapy: lateral or elevated-head sleep for documented positional OSA (supine AHI at least twice non-supine).
• Avoidance of respiratory depressants: alcohol, benzodiazepines, and opioids blunt genioglossus tone and arousal threshold and are relatively contraindicated.

First-line definitive therapy

• Positive airway pressure: PAP is the first-line therapy when treatment is indicated, across severity levels. The AASM 2019 PAP guideline strongly recommends PAP for OSA with excessive sleepiness and conditionally suggests it for impaired sleep-related quality of life and for comorbid hypertension; asymptomatic mild OSA may reasonably be managed initially with weight loss, positional, and behavioral measures. CPAP works as a pneumatic splint, raising intraluminal pressure above Pcrit. Auto-titrating PAP (APAP) is an acceptable alternative for uncomplicated OSA; BPAP is used for pressure intolerance or coexisting hypoventilation. Adherence (commonly benchmarked at ≥4 hours nightly) is the main determinant of benefit and should be objectively downloaded, not assumed.

Escalation / CPAP-intolerant patients

• Oral appliances: custom mandibular advancement devices (AASM/American Academy of Dental Sleep Medicine 2015 guideline) for mild–moderate OSA or CPAP refusal; they pull the tongue base forward.
• Hypoglossal nerve stimulation: implanted stimulator for selected patients with moderate–severe OSA, CPAP failure, BMI below device limits, and absence of complete concentric palatal collapse on drug-induced sleep endoscopy.
• Upper airway surgery: tonsillectomy for obstructing tonsils, uvulopalatopharyngoplasty, nasal surgery, and maxillomandibular advancement (the most effective skeletal procedure). Tracheostomy bypasses the pharynx entirely and is reserved for life-threatening disease.
• Adenotonsillectomy is first-line in children with adenotonsillar hypertrophy per the American Academy of Pediatrics.

Residual sleepiness and contraindications

• Wake-promoting agents: modafinil, armodafinil, or solriamfetol only for persistent sleepiness despite adequate PAP use — never as a substitute for airway therapy.
• Supplemental oxygen alone is not treatment: it may raise SpO₂ while apneas, arousals, and hypercapnia continue, and can prolong events. A common exam distractor.

Cardiovascular (driven by intermittent hypoxia, sympathetic surge, and negative intrathoracic pressure)

• Resistant hypertension: sustained sympathetic overactivity and impaired nocturnal dipping; signaled by non-dipping or reverse-dipping on ambulatory BP monitoring. OSA is the most common identifiable cause of secondary/resistant hypertension.
• Atrial fibrillation: atrial stretch from extreme negative intrathoracic pressure plus vagal-sympathetic swings; the signal is recurrence after cardioversion or ablation despite antiarrhythmic therapy.
• Bradyarrhythmias and nocturnal sudden cardiac death: vagally mediated sinus pauses and AV block during apneas; nocturnal-predominant events distinguish OSA-related death from the typical morning peak of coronary events. Emergency.
• Heart failure and pulmonary hypertension/cor pulmonale: increased LV transmural pressure and afterload plus hypoxic pulmonary vasoconstriction; look for elevated JVP, edema, and RV strain on echocardiography.
• Stroke and coronary disease: accelerated by endothelial dysfunction and a prothrombotic state.

Metabolic, hematologic, and neurocognitive

• Insulin resistance and type 2 diabetes, secondary erythrocytosis from chronic hypoxemia (elevated hematocrit with normal-appearing lungs by day), cognitive impairment and depression.
• Motor vehicle and occupational accidents: the most underappreciated lethal complication; mandates counseling and, in commercial drivers, reporting per state and DOT rules.

Respiratory decompensation

• Obesity hypoventilation syndrome / acute hypercapnic respiratory failure: awake PaCO₂ >45 mmHg with somnolence, headache, and elevated bicarbonate; may present as CO₂ narcosis requiring noninvasive ventilation. Emergency.
• Perioperative and opioid-related airway obstruction: sedatives abolish the arousal reflex that terminates apneas, producing postoperative hypoxemia, respiratory arrest, or death. Emergency — screen with STOP-BANG preoperatively.

Treatment-related

• CPAP: nasal dryness/epistaxis, aerophagia, mask-related skin breakdown and air-leak conjunctivitis, claustrophobia, and treatment-emergent central sleep apnea (complex sleep apnea) from CO₂ overshoot below the apneic threshold.
• Oral appliances: temporomandibular pain and permanent occlusal change.
• Upper airway surgery: postoperative bleeding, velopharyngeal insufficiency and nasopharyngeal stenosis after uvulopalatopharyngoplasty, and post-adenotonsillectomy respiratory compromise in children with severe OSA, who require inpatient monitoring.

• The classic stem: an obese middle-aged man with loud snoring, bed-partner–*witnessed apneas with gasping*, morning headache, and daytime somnolence. Best next step: polysomnography (or home sleep apnea testing if the pretest probability is high and there is no cardiopulmonary comorbidity) — not an Epworth score, not empiric CPAP.
• The association examiners test most: OSA and resistant hypertension with loss of nocturnal BP dipping, and OSA as the reason atrial fibrillation recurs after cardioversion or ablation. Treating OSA improves rhythm control.
• Obstructive vs central: obstructive apnea shows absent airflow with continued respiratory effort; central apnea shows absent airflow and absent effort. Cheyne–Stokes crescendo–decrescendo breathing in a heart failure patient points to central sleep apnea, not OSA.
• Severity numbers worth memorizing: AHI ≥5 to <15 mild, ≥15 to <30 moderate, ≥30 severe; diagnosis requires AHI ≥5 with symptoms/comorbidity or ≥15 without.
• The commonest distractor: supplemental oxygen alone — it raises SpO₂ but does not splint the airway, does not abolish arousals, and may worsen hypercapnia. PAP is the answer.
• Sedatives kill here: benzodiazepines, opioids, and alcohol suppress genioglossus tone and the arousal that terminates each apnea. Preoperative STOP-BANG screening and postoperative monitoring are the American Society of Anesthesiologists' concern; unmonitored opioid dosing after surgery is a classic fatal-outcome vignette.
• Pediatric OSA looks different: adenotonsillar hypertrophy, mouth breathing, enuresis, failure to thrive, and hyperactivity/inattention mimicking ADHD rather than sleepiness; AHI >1 is abnormal and adenotonsillectomy is first-line (American Academy of Pediatrics).
• Don't miss the hypoventilator: an obese somnolent patient with awake PaCO₂ >45 mmHg and elevated serum bicarbonate has obesity hypoventilation syndrome. Match the therapy to the setting per the ATS 2019 OHS guideline:
• Acute hypercapnic decompensation / CO₂ narcosis: noninvasive ventilation (BPAP) in a monitored setting.
• Stable ambulatory OHS with coexisting severe OSA (the majority): CPAP is a guideline-suggested first-line option, with escalation to BPAP if hypercapnia or nocturnal hypoxemia persists.
• OHS without severe OSA (sleep hypoventilation phenotype): nocturnal NIV.
• Unexplained erythrocytosis in a snorer should prompt a sleep study before an extensive hematologic workup.